AIDS research and therapy · 2026
Effect of dolutegravir-based antiretroviral therapy transition on body mass index in adolescents living with HIV: secondary analysis of data from the ANRS 12225 Pediacam III cohort in Cameroon.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Noumsi Thierry Serge Joël, Sandie Arsène Brunelle, Ateba Ndongo Francis, Tetang Ndiang Suzie, Guemkam Georgette, Mbouchong Verlaine Bolyse, Fossi Mireille, Penda Ida Calixte, Tchatchueng Mbougua Jules Brice, Faye Albert, Warszawski Josiane, Tejiokem Mathurin Cyrille
Аннотация
BACKGROUND: Dolutegravir (DTG) is widely used in people living with HIV, but its potential association with weight gain remains insufficiently documented in adolescents. This study assessed the effect of transitioning to a DTG-based regimen on body mass index (BMI) in adolescents living with HIV (ALHIV) in Cameroon.
METHODS: Data prospectively collected between 2020 and 2024 from the ANRS 12,225-Pediacam III cohort were retrospectively analyzed. The analysis included 105 ALHIV who switched to DTG (HI-DTG), 18 ALHIV who did not (HI-nDTG), and 180 HIV-uninfected adolescents born to HIV-positive mothers (HEU, n = 79) or to HIV-negative mothers (HUU, n = 101). Body mass index (BMI) trajectories and levels were compared across groups using linear mixed-effects models, as well as before and after the DTG transition within the HI-DTG group.
RESULTS: The median age was 11.5 years (IQR:11.0-12.5), which significant differences between groups. Overall, 51.6% were female. The median follow-up on DTG was 2.6 years (IQR:2.0-3.2). BMI trajectories differed across groups (p = 0.045) after adjustment for sex, age, baseline BMI z-score, household income, and interaction terms. Compared with HI-nDTG as the reference group, the HI-DTG group showed a modest but significant greater annual increase in BMI (0.32 kg/m²/year; 95% CI: 0.03-0.62; p = 0.03), with no differences observed for HEU or HUU. Baseline BMI z-score, household income, and female sex were more strongly associated with BMI over time than DTG use. Within the HI-DTG group, a mean annual increase of 0.19 kg/m²/year was observed after switching to DTG.
CONCLUSION: Switching to DTG was associated with an increase in BMI among ALHIV. These findings underscore the need for close metabolic monitoring to prevent long-term cardiometabolic complications.
METHODS: Data prospectively collected between 2020 and 2024 from the ANRS 12,225-Pediacam III cohort were retrospectively analyzed. The analysis included 105 ALHIV who switched to DTG (HI-DTG), 18 ALHIV who did not (HI-nDTG), and 180 HIV-uninfected adolescents born to HIV-positive mothers (HEU, n = 79) or to HIV-negative mothers (HUU, n = 101). Body mass index (BMI) trajectories and levels were compared across groups using linear mixed-effects models, as well as before and after the DTG transition within the HI-DTG group.
RESULTS: The median age was 11.5 years (IQR:11.0-12.5), which significant differences between groups. Overall, 51.6% were female. The median follow-up on DTG was 2.6 years (IQR:2.0-3.2). BMI trajectories differed across groups (p = 0.045) after adjustment for sex, age, baseline BMI z-score, household income, and interaction terms. Compared with HI-nDTG as the reference group, the HI-DTG group showed a modest but significant greater annual increase in BMI (0.32 kg/m²/year; 95% CI: 0.03-0.62; p = 0.03), with no differences observed for HEU or HUU. Baseline BMI z-score, household income, and female sex were more strongly associated with BMI over time than DTG use. Within the HI-DTG group, a mean annual increase of 0.19 kg/m²/year was observed after switching to DTG.
CONCLUSION: Switching to DTG was associated with an increase in BMI among ALHIV. These findings underscore the need for close metabolic monitoring to prevent long-term cardiometabolic complications.